TABLE 1

Characteristics of patient samples

Populationn (male/female)Age (years)BMI (kg/m2)Fasting plasma glucose (mmol/l)HbA1c (%)* or plasma glucose at 2-h OGTT (mmol/l)†
Scandinavia trios
    Probands168/15339 ± 927 ± 57.2 ± 2.68.5 ± 2.9†
    Parents236/236
Sibships
    Diabetes/severe IGT sib280/32965 ± 1029 ± 59.3 ± 3.314.3 ± 5.6†
    NGT sib275/30562 ± 1026 ± 35.4 ± 0.46.0 ± 1.1†
Scandinavia case/control
    Diabetes/severe IGT252/21960 ± 1028 ± 59.8 ± 3.415.0 ± 5.3†
    NGT254/21760 ± 1027 ± 46.2 ± 1.86.8 ± 2.8†
Sweden case/control
    Diabetes/severe IGT267/24766 ± 1228 ± 49.6 ± 2.96.5 ± 1.5*
    NGT267/24766 ± 1228 ± 45.5 ± 0.7ND
Canada case/control
    Diabetes70/5753 ± 829 ± 56.4 ± 1.812.8 ± 2.1†
    NGT70/5752 ± 829 ± 45.1 ± 0.66.1 ± 1.1†
U.S. case/control
    Diabetes644/58263 ± 1133 ± 79.8 ± 3.08.0 ± 3.1*
    NGT644/58261 ± 1027 ± 55.1 ± 0.9ND
Poland case/control
    Diabetes422/58762 ± 1030 ± 58.9 ± 4.07.9 ± 1.3*
    NGT422/58759 ± 726 ± 44.8 ± 1.2ND
  • Data are means ± SD. Plasma glucose was measured at baseline (fasting) and 2 h after an OGTT. Severe impaired glucose tolerance (IGT) was defined as an OGTT 2-h blood glucose ≥8.5 mmol/l but <10.0 mmol/l. ND, not determined; NGT, normal glucose tolerance.